SCHEDULE F(Form 990)
Department of the Treasury
Internal Revenue Service
Statement of Activities Outside the United States
Right pointing arrow large image Complete if the organization answered "Yes" to Form 990,Part IV, line 14b, 15, or 16.Right pointing arrow large image Attach to Form 990. Right pointing arrow large image See separate instructions.Right pointing arrow large image Information about Schedule F (Form 990) and its instructions is at www.irs.gov/form990.
OMB No. 1545-0047
2015
Open to Public Inspection
Name of the organization
JDRF INTERNATIONAL
 
Employer identification number

23-1907729
Part I
General Information on Activities Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 14b.
1
For grantmakers.Does the organization maintain records to substantiate the amount of its grants and
other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used
to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .
2
For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.
3
Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)
(a) Region (b) Number of offices in the region (c) Number of employees, agents, and independent contractors in region (d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region) (e) If activity listed in (d) is a program service, describe specific type of
service(s) in region		 (f) Total expenditures
for and investments
in region
North America     Grantmaking RESEARCH GRANTS 3,602,196
Europe (Including Iceland and Greenland)     Grantmaking RESEARCH GRANTS 15,748,328
Middle East and North Africa     Grantmaking RESEARCH GRANTS 904,943
East Asia and the Pacific     Grantmaking RESEARCH GRANTS 3,635,315
Central America and the Caribbean     Investments INVESTMENTS 7,883,322
Europe (Including Iceland and Greenland) 1 1 Program Services RESEARCH ADMINSTRATION 310,350
           
           
           
           
           
           
           
           
           
           
           
3a Sub-total ..... 1 1 32,084,454
b Total from continuation sheets to Part I ...      
c Totals (add lines 3a and 3b) 1 1 32,084,454
For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2015
Page 2
Schedule F (Form 990) 2015
Page 2
Part II
Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.
1 (a) Name of organization (b) IRS code section
and EIN (if applicable)		 (a)(c) Region (b)(d) Purpose of
grant 		(e) Amount of
cash grant 		(f) Manner of
cash
disbursement 		(g) Amount
of non-cash
assistance 		(h) Description
of non-cash
assistance 		(i) Method of
valuation
(book, FMV,
appraisal, other)
East Asia and the Pacific   500,248 CHECK/WIRE   N/A N/A
North America   84,967 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   85,604 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   1,107,939 CHECK/WIRE   N/A N/A
Middle East and North Africa   604,943 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   204,690 CHECK/WIRE   N/A N/A
East Asia and the Pacific   503,712 CHECK/WIRE   N/A N/A
East Asia and the Pacific   647,910 CHECK/WIRE   N/A N/A
East Asia and the Pacific IMMUNE THERAPIES 109,286 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   167,431 CHECK/WIRE   N/A N/A
East Asia and the Pacific   366,034 CHECK/WIRE   N/A N/A
North America   371,778 CHECK/WIRE   N/A N/A
North America   910,685 CHECK/WIRE   N/A N/A
North America IMMUNE THERAPIES 464,420 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 113,012 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 392,055 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   199,941 CHECK/WIRE   N/A N/A
North America   437,974 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   246,031 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   196,293 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 100,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 280,011 CHECK/WIRE   N/A N/A
East Asia and the Pacific   89,116 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   388,837 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 406,440 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 300,000 CHECK/WIRE   N/A N/A
North America IMMUNE THERAPIES 535,904 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   184,651 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) GLUCOSE CONTROL 113,012 CHECK/WIRE   N/A N/A
East Asia and the Pacific   603,778 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   334,961 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 144,203 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 448,624 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   789,737 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   533,696 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   119,993 CHECK/WIRE   N/A N/A
North America   242,280 CHECK/WIRE   N/A N/A
East Asia and the Pacific ARTIFICIAL PANCREAS 200,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   321,225 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   193,261 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   175,991 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   451,725 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   200,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   2,808,551 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   79,484 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   58,660 CHECK/WIRE   N/A N/A
East Asia and the Pacific   250,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   150,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   561,994 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland)   303,415 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) BETA CELL 156,250 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) PREVENTION 90,787 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 253,478 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) BETA CELL 65,231 CHECK/WIRE   N/A N/A
North America REGENERATION 250,000 CHECK/WIRE   N/A N/A
North America COMPLICATIONS 104,188 CHECK/WIRE   N/A N/A
Middle East and North Africa REGENERATION 300,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) REGENERATION 55,014 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 56,506 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) BETA CELL 356,250 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) ARTIFICAL PANCREAS 1,140,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) REGENERATION 180,000 CHECK/WIRE   N/A N/A
East Asia and the Pacific IMMUNE THERAPIES 365,231 CHECK/WIRE   N/A N/A
North America IMMUNE THERAPIES 200,000 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 109,991 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 326,009 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 574,729 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 112,616 CHECK/WIRE   N/A N/A
Europe (Including Iceland and Greenland) IMMUNE THERAPIES 110,000 CHECK/WIRE   N/A N/A
2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......MediumBullet
 
3 Enter total number of other organizations or entities .......................MediumBullet
69
Schedule F (Form 990) 2015
Page 3
Schedule F (Form 990) 2015Page 3
Part III
Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.
Part III can be duplicated if additional space is needed.
(a) Type of grant or assistance (b) Region (c) Number of recipients (d) Amount of
cash grant 		(e) Manner of cash
disbursement 		(f) Amount of
non-cash
assistance 		(g) Description
of non-cash
assistance 		(h) Method of
valuation
(book, FMV,
appraisal, other)
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
Schedule F (Form 990) 2015
Page 4
Schedule F (Form 990) 2015
Page 4
Part IV
Foreign Forms
1 Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes,"the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .
5 Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships. (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Schedule F (Form 990) 2015
Page 5
Schedule F (Form 990) 2015
Page 5
Part V
Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information (see instructions).
ReturnReference Explanation
GRANT MONITORING PROCEDURES SCH-F PART I LINE 2 Research grants are awarded by the recommendations of a professional scientific staff at JDRF based on input from outside scientific reviewers and patient advocates. The following areas are evaluated: (1) The scientific merit of the application. (2) The relationship of the research to the causes, treatment, prevention and cure of diabetes and its complications. Also considered are the merits of the institutions and/or sponsors of the applicant, and the applicant's commitment to the continuing diabetes research programs. JDRF staff reviews expenditures reported by an institution.
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Schedule F (Form 990) 2015
Additional Data


Software ID:  
Software Version: